Sugi Predict

Sugi Predict / Compounds / SCHEMBL229441

SCHEMBL229441

SCHEMBL229441

O=C(Cl)c1ccccc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCAT2 O15382 1/20 0.63
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ CHRNB2 P17787 4/20 0.55
▸ CHRNB4 P30926 4/20 0.55
▸ CHRNA3 P32297 4/20 0.55
▸ CHRNA4 P43681 4/20 0.55
▸ HNF4A P41235 1/20 0.53
▸ TSHR P16473 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ ALDH1A1 P00352 4/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ FABP3 P05413 1/20 0.48
▸ FABP4 P15090 1/20 0.48
▸ FABP5 Q01469 1/20 0.48
▸ HTT P42858 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18825620 0.96 BCAT2 (0.59) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL9532086 0.93 BCAT2 (0.55) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL3297211 0.91 BCAT2 (0.53) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL28004514 0.86 PTGER1 (0.50) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL993303 0.85 ALDH1A1 (0.58) BCAT2MEN1KMT2ASMN1; SMN2HNF4A
SCHEMBL29688494 0.85 ALDH1A1 (0.58) BCAT2MEN1KMT2ASMN1; SMN2HNF4A
SCHEMBL29697585 0.85 BCAT2 (0.47) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL28640320 0.85 SLC6A3 (0.64) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL29697586 0.85 BCAT2 (0.47) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL31397037 0.85 HNF4A (0.49) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115286514-B Preparation method of 4' -chloro-2-aminobiphenyl sulfate 山东京博农化科技股份有限公司 2024-01-12 — — CN claimed
CN-113831280-B Preparation method of boscalid 上海埃农生物科技有限公司 2023-08-15 — — CN claimed
CN-115286514-A Preparation method of 4' -chloro-2-aminobiphenyl sulfate 京博农化科技有限公司 2022-11-04 — — CN claimed
CN-113831280-A Preparation method of boscalid 上海埃农生物科技有限公司 2021-12-24 — — CN claimed
CN-113502491-A Electrochemical preparation method of Tioxazafen and atrareum intermediate 湖南大学 2021-10-15 — — CN claimed
CN-107001221-A method for preparing treprostinil 奇诺因药物和化学工厂私人有限公司 2017-08-01 — — CN claimed
EP-2160397-B1 A NOVEL AND HIGHLY STEREOSELECTIVE PROCESS FOR PREPARING GEMCITABINE AND INTERMEDIATES THEREOF NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) 2014-03-26 — — EP claimed
US-20130018181-A1 Novel and Highly Stereoselective Process for Preparing Gemcitabine and Intermediates Thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2013-01-17 — — US claimed
CN-102153601-A Method for preparing gemcitabine hydrochloride and intermediate thereof with high selectivity HUNAN OUYA BIOLOG CO LTD 2011-08-17 — — CN claimed
US-20100179314-A1 Novel and Highly Stereoselective Process for Preparing Gemcitabine and Intermediates Thereof NANJING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., (CN) 2010-07-15 — — US claimed
EP-2160397-A1 A NOVEL AND HIGHLY STEREOSELECTIVE PROCESS FOR PREPARING GEMCITABINE AND INTERMEDIATES THEREOF Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2010-03-10 — — EP claimed
WO-2008144970-A1 A NOVEL AND HIGHLY STEREOSELECTIVE PROCESS FOR PREPARING GEMCITABINE AND INTERMEDIATES THEREOF Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2008-12-04 — — WO claimed
US-20020062043-A1 Process for preparing optionally substituted biphenylcarbonyl chlorides BAYER AKTIENGESELLSCHAFT (DE) 2002-05-23 — — US claimed
JP-63216849-A — — None — — JP disclosed
JP-2258745-A — — None — — JP disclosed
CN-119504570-A Benzamide compound, pharmaceutical composition and application 徐州医科大学 2025-02-25 — — CN disclosed
US-4003911-A ANTISECRETORY AGENTS, OXYTOCICS, BRONCHODILATORS, PLASTICIZERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-01-18 — — US disclosed
US-3965093-A 6-Arylthio penicillanic acid and derivatives thereof E. R. SQUIBB & SONS, INC. (US) 1976-06-22 — — US disclosed
US-3959277-A Diimidazopyrazines and tetracarboxamidopyrazines E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-05-25 — — US disclosed
US-3954744-A ANTIBACTERIAL E. R. SQUIBB & SONS, INC. (US) 1976-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179314-A1 Novel and Highly Stereoselective Process for Preparing Gemcitabine and Intermediates Thereof KRAS, TYMP, TYMS BCAT2 2797/4885MEN1 2059/4885KMT2A 2837/4885
US-20020062043-A1 Process for preparing optionally substituted biphenylcarbonyl chlorides OTC, DDT, ODC1 BCAT2 1956/4885MEN1 1163/4885KMT2A 1493/4885
US-20130018181-A1 Novel and Highly Stereoselective Process for Preparing Gemcitabine and Intermediates Thereof KRAS, TYMP, TYMS BCAT2 2797/4885MEN1 2059/4885KMT2A 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.